A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
3/7/2024, 9:08 AMSummary of Bill S 3220
Bill 118 s 3220, also known as the "Tropical Disease Product Priority Review Voucher Program Expansion Act," aims to expand the existing priority review voucher program to include coccidioidomycosis, a fungal infection commonly found in the southwestern United States.The priority review voucher program was originally established to incentivize pharmaceutical companies to develop treatments for neglected tropical diseases by offering them a voucher that can be used to expedite the review process for another drug. This bill seeks to include coccidioidomycosis in this program, recognizing the importance of preventing and treating this disease, which can be severe and even fatal in some cases.
By expanding the priority review voucher program to include coccidioidomycosis, this bill aims to encourage pharmaceutical companies to invest in research and development for treatments and prevention methods for this disease. This could lead to the development of new and more effective drugs to combat coccidioidomycosis, ultimately benefiting those who are at risk of contracting this infection. Overall, Bill 118 s 3220 seeks to address the public health concern of coccidioidomycosis by providing incentives for pharmaceutical companies to focus on developing treatments and prevention methods for this disease. This could potentially lead to advancements in medical research and improved outcomes for individuals affected by coccidioidomycosis.
Congressional Summary of S 3220
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Read the Full Bill
Current Status of Bill S 3220
Bill S 3220 is currently in the status of Bill Introduced since November 2, 2023. Bill S 3220 was introduced during Congress 118 and was introduced to the Senate on November 2, 2023. Bill S 3220's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of November 2, 2023Bipartisan Support of Bill S 3220
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
8Democrat Cosponsors
4Republican Cosponsors
2Unaffiliated Cosponsors
2Policy Area and Potential Impact of Bill S 3220
Primary Policy Focus
HealthAlternate Title(s) of Bill S 3220
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.Comments
Most relevant
Sponsors and Cosponsors of S 3220
Latest Bills
A bill to establish a Youth Mental Health Research Initiative in the National Institutes of Health for purposes of encouraging collaborative research to improve youth mental health.
Bill S 1266April 4, 2025
ADS for Mental Health Services Act
Bill S 414April 4, 2025
Drug Competition Enhancement Act
Bill S 1040April 4, 2025
PARSA
Bill S 928April 4, 2025
A bill to promote exports by creative industries and occupations, and for other purposes.
Bill S 1125April 4, 2025
A bill to amend section 2284 of title 28, United States Code, to establish special procedures for civil actions seeking to restrain executive branch actions.
Bill S 1090April 4, 2025
PARC Act
Bill S 1037April 4, 2025
Preserve Access to Affordable Generics and Biosimilars Act
Bill S 1096April 4, 2025
Farewell to Foam Act of 2025
Bill S 897April 4, 2025
A bill to unfreeze funding for contract of the Department of Agriculture, to prohibit Farm Service Agency and Natural Resources Conservation Service office closures, and for other purposes.
Bill S 1172April 4, 2025
FORWARD Act of 2023
Bill S 3464January 22, 2024
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
Bill HR 6227February 6, 2024